<DOC>
	<DOCNO>NCT00023361</DOCNO>
	<brief_summary>Primary objective : To determine rate confirm treatment failure relapse intermittent rifabutin-based regimen treatment isoniazid rifamycin-susceptible HIV-related tuberculosis ( TB ) .</brief_summary>
	<brief_title>TBTC Study 23 : Treatment HIV-Related Tuberculosis Using Rifabutin-Based Regimen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis pulmonary &amp; /or extrapulmonary TB confirm positive culture susceptibility rifampin . Patients isoniazid pyrazinamide ( PZA ) resistant isolates eligible continue study modify regimen Evidence HIV infection confirm positive serologic test ( ELISA Western Blot ) . Absolute neutrophil count &gt; 500/mm3 ( use colony stimulate factor , filgrastim , sargramostim allow ) &gt; 18 year age Willingness practice effective contraception applicable Signed informed consent Exclusion Criteria Pregnancy breastfeed AST &gt; 10 time upper limit normal Bilirubin &gt; 3.0 time upper limit normal Creatinine &gt; 3.0 time upper limit normal Intolerance study drug except isoniazid pyrazinamide Concomitant disorder contraindication use study drug More 28 day treatment active tuberculosis within 6 month prior course therapy Bone/joint tuberculosis silicotuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>